National Institute for Health and Care Excellence

Published: Guidance, quality standards and advice

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity TA1152 7 May 2026 7 May 2026 Zanidatamab for treating ...
The National Institute for Health and Care Excellence

New machines that keep donor livers alive outside the body could help hundreds waiting for a life-saving transplant

A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving ...
The National Institute for Health and Care Excellence

Neonatal infection guidance updated to allow home antibiotic treatment for some babies

This means mothers whose babies need antibiotics could leave hospital sooner and complete treatment at home with full clinical support, potentially reducing their hospital stay by up to 2.7 days. All ...
The National Institute for Health and Care Excellence

Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families

The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...
National Institute for Health and Care Excellence

NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity TA1152 7 May 2026 7 May 2026 Zanidatamab for treating ...
National Institute for Health and Care Excellence

Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...
National Institute for Health and Care Excellence

Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care

This guidance has been updated and replaced by NICE guideline CG182 ...
National Institute for Health and Care Excellence

Quality statement 6: Emergency oxygen during an exacerbation

During an exacerbation, people with COPD may experience a worsening of gas exchange in the lungs, which can lead to low blood oxygen levels. Emergency oxygen is often given during the treatment of an ...
National Institute for Health and Care Excellence

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.